Taranjeet Jolly, MD
Interventional Pain Medicine · Abingdon, MDNPI 1689954059
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (44.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 21.6%. 2025 is the largest year on record at $1,545, more than ten times the $40 reported in 2020. That places this record below the midpoint for interventional pain medicine clinicians in MD, where the typical reported total is $3,506.
Across 33 payments — averaging $88.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$633
- Medtronic$546
- Bioventus LLC$506
- Curonix LLC$407
- Teladoc Health, Inc.$250
- Medical Device Business Services, Inc.$137
- plus $447 from 7 others
What the payments were for
- Consulting fees$2509%
- Travel & lodging$1,30345%
- Food & beverage$1,23642%
- Education$1375%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $633 |
| Medtronic(2 entities) | 7 | $546 |
| Bioventus LLC | 4 | $506 |
| Curonix LLC | 2 | $407 |
| Teladoc Health, Inc. | 1 | $250 |
| Medical Device Business Services, Inc. | 1 | $137 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| MML US, Inc. | 2 | $114 |
| SPR Therapeutics, Inc | 1 | $80 |
| Stryker | 2 | $66 |
| Johnson & Johnson | 1 | $27 |
| Boston Scientific | 1 | $19 |
| Fidia Pharma USA Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,926 in reported general payments places this provider in the 40th percentile of 56 interventional pain medicine providers in Maryland.
See all interventional pain medicine providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 30 | $465 |
| Cyclobenzaprine Hcl | 20 | $457 |
| Diclofenac Sodium | 14 | $367 |
| Tizanidine Hcl | 15 | $117 |
| Meloxicam | 13 | $50 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Abingdon
- Mark ColemanPikesville$1.3M
- Marc LoevRockville$318K
- Anish PatelFrederick$311K
- Aneesh SinglaSalisbury$167K
- Charles SimmonsAnnapolis$62K
- Ali El-MohandesHagerstown$57K
- Michael WongBel Air$31K
- Anna IrwinBethesda$30K
- Dontese NicholsonBaltimore$27K
- Rajesh JariNottingham$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.